Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

← The archive

archived as published

Friday, 23 October · prices through NSE close

RBI schedules October auctions for securities and repos, and 5 more corroborated developments

1

RBI schedules October auctions for securities and repos

The Reserve Bank of India will conduct an underwriting auction for Government Securities totaling ₹33,000 crore on October 23, 2026, and will also conduct a 3-day Variable Rate Repo auction under Liquidity Adjustment Facility on the same date. The RBI conducted Overnight Variable Rate Repo auctions on October 21 and October 22, 2026, each with a notified amount of ₹50,000 crore, with the October 22 auction having a cut off rate of 5.54%.

regulatoryorg.inindiatimes.comthehindubusinessline.com+11+10corroborated · 13 sourcesCited record →
2

Bajaj Finance reports 29% rise in Q2 profit

Bajaj Finance reported a 29% year-on-year rise in consolidated net profit to Rs 6,367 crore for the July-September quarter of FY27.

3

Reliance shares rise on Jio IPO strong demand

Reliance Industries shares rose nearly 3% on Wednesday as subsidiary Jio Platforms' Rs 30,213 crore IPO opened to strong demand, achieving full subscription within an hour. The IPO was open for subscription from October 21 to 23.

share moveindiatimes.comlivemint.comcnbctv18.com+9+8corroborated · 11 sourcesCited record →
4

Paras Healthcare IPO opens at Rs 660-693 per share

Paras Healthcare's Rs 1,450 crore initial public offering opened for subscription on October 21 and closes on October 23, with a price band of Rs 660-693 per equity share. The offering showed a grey market premium of around 7%.

5

IRDAI open to extending distribution reform feedback deadline

regulatoryndtvprofit.comlivemint.comindiatimes.com+5+4corroborated · 7 sourcesCited record →
6

Hindustan Zinc net profit surges 142 percent year-on-year

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.